Targeting TET1 with a small molecule inhibitor improved metabolic indexes in mice fed with an HFD, thereby providing the preclinical evidence that targeting liver TET1 is a potential therapeutic approach in patients with MASLD. The gene discussed is TET1; the disease is metabolic dysfunction-associated steatotic liver disease.